相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Preclinical Characterization of Linrodostat Mesylate, a Novel, Potent, and Selective Oral Indoleamine 2,3-Dioxygenase 1 Inhibitor
Aaron Balog et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib
Christin Riess et al.
FRONTIERS IN IMMUNOLOGY (2020)
Prognostic impact of indoleamine 2,3-dioxygenase 1(IDO1)mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma
Panagiota Economopoulou et al.
ESMO OPEN (2020)
IDO Expression in Cancer: Different Compartment, Different Functionality?
Annabel Meireson et al.
FRONTIERS IN IMMUNOLOGY (2020)
Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity
Henrique Lemos et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Kyung Hae Jung et al.
CLINICAL CANCER RESEARCH (2019)
Targeting Immune-Related Molecules in Cancer Therapy: A Comprehensive In Vitro Analysis on Patient-Derived Tumor Models
Claudia Maletzki et al.
BIOMED RESEARCH INTERNATIONAL (2019)
Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients
Hong Wang et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2019)
In vitro humanized 3D microfluidic chip for testing personalized immunotherapeutics for head and neck cancer patients
Ahmed Al-Samadi et al.
EXPERIMENTAL CELL RESEARCH (2019)
Immune gene expression in head and neck squamous cell carcinoma patients
Charlotte Lecerf et al.
EUROPEAN JOURNAL OF CANCER (2019)
DNA methylation of indoleamine 2,3-dioxygenase 1 (IDO1) in head and neck squamous cell carcinomas correlates with IDO1 expression, HPV status, patients’ survival, immune cell infiltrates, mutational load, and interferon γ signature
Verena Sailer et al.
EBioMedicine (2019)
A two-CpG-based prognostic signature for oral squamous cell carcinoma overall survival
Yanping Chen et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2019)
Immune control by amino acid catabolism during tumorigenesis and therapy
Henrique Lemos et al.
NATURE REVIEWS CANCER (2019)
Indoleamine 2,3-Dioxygenase Expression in Primary Cutaneous Melanoma Correlates with Breslow Thickness and Is of Significant Prognostic Value for Progression-Free Survival
Felicia Rubel et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1
Erik A. Dill et al.
MODERN PATHOLOGY (2018)
Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme
Todd A. Triplett et al.
NATURE BIOTECHNOLOGY (2018)
Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments
Benjamin Solomon et al.
SEMINARS IN CANCER BIOLOGY (2018)
Peritumoral endothelial indoleamine 2, 3-dioxygenase expression is an early independent marker of disease relapse in colorectal cancer and is influenced by DNA mismatch repair profile
Annabel Meireson et al.
Oncotarget (2018)
Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas
Joshua D. Campbell et al.
CELL REPORTS (2018)
Matrix metalloproteinase (MMP) and immunosuppressive biomarker profiles of seven head and neck squamous cell carcinoma (HNSCC) cell lines
Amber M. Bates et al.
TRANSLATIONAL CANCER RESEARCH (2018)
Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors
Asha Nayak-Kapoor et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study
Aung Naing et al.
CANCER RESEARCH (2018)
Integrated Comprehensive Analysis of Immune Cell Subsets and Assessment of Checkpoint Inhibitor Response in Head and Neck Squamous Cell Carcinoma, Urothelial Carcinoma and Renal Cell Carcinoma 3D Ex Vivo
Melba Marie Page et al.
CANCER RESEARCH (2018)
Characterization of the tumor immune microenvironment in head and neck squamous cell carcinoma (SCCHN)
Farah Succaria et al.
CANCER RESEARCH (2018)
Discovery of DN-016: A highly potent, selective and orally available IDO1 inhibitor for treating cancers
Shoujun Chen et al.
CANCER RESEARCH (2018)
Targeting the kynurenine pathway as a novel metabolic treatment for head and neck cancer
Chitra Subramanian et al.
CANCER RESEARCH (2018)
Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8+ T Cells in Head and Neck Cancer
Krishna et al.
CANCER RESEARCH (2018)
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Tara C. Mitchell et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
LBA15Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas
K J Harrington et al.
ANNALS OF ONCOLOGY (2018)
Current studies of immunotherapy in head and neck cancer
V. Dogan et al.
CLINICAL OTOLARYNGOLOGY (2018)
IDO Immune Status after Chemoradiation May Predict Survival in Lung Cancer Patients
Weili Wang et al.
CANCER RESEARCH (2018)
Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'
George C. Prendergast et al.
TRENDS IN CANCER (2018)
Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: Updated phase 1 results from ECHO-202/KEYNOTE-037
T.C. Gangadhar et al.
ANNALS OF ONCOLOGY (2017)
ATIM-29. A PHASE 1 STUDY OF PF-06840003, AN ORAL INDOLE 2,3-DIOXYGENASE 1 (IDO1) INHIBITOR IN PATIENTS WITH MALIGNANT GLIOMAS
David Reardon et al.
NEURO-ONCOLOGY (2017)
Cell genomics and immunosuppressive biomarker expression influence PD-L1 immunotherapy treatment responses in HNSCC-a computational study
Amber M. Bates et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2017)
UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival Analyses
Darshan S. Chandrashekar et al.
NEOPLASIA (2017)
IDO1 as a mechanism of adaptive immune resistance to anti-PD1 monotherapy in HNSCC.
Lori J. Wirth et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Epacadostat plus nivolumab in patients with advanced solid tumors: Preliminary phase I/II results of ECHO-204.
Raymond P. Perez et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Epacadostat plus pembrolizumab in patients with SCCHN: Preliminary phase VII results from ECHO-202/KEYNOTE-037.
Omid Hamid et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety of epacadostat 100 mg bid plus pembrolizumab 200 mg Q3W in advanced solid tumors: Phase 2 data from ECHO-202/KEYNOTE-037.
Omid Hamid et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade
J. -P. Foy et al.
ANNALS OF ONCOLOGY (2017)
BMS-986205, an optimized indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor, is well tolerated with potent pharmacodynamic (PD) activity, alone and in combination with nivolumab (nivo) in advanced cancers in a phase 1/2a trial
Lillian L. Siu et al.
CANCER RESEARCH (2017)
The expression and prognostic relevance of indoleamine 2,3-dioxygenase in tongue squamous cell carcinoma
Miia Seppala et al.
ACTA OTO-LARYNGOLOGICA (2016)
STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation
Henrique Lemos et al.
CANCER RESEARCH (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Relationship between indoleamine 2,3-dioxygenase activity and lymphatic invasion propensity of colorectal carcinoma
Atilla Engin et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Interferon gamma-induced apoptosis of head and neck squamous cell carcinoma is connected to indoleamine-2,3-dioxygenase via mitochondrial and ER stress-associated pathways
Siraj M. El Jamal et al.
CELL DIVISION (2016)
Activated STING enhances Tregs infiltration in the HPV-related carcinogenesis of tongue squamous cells via the c-jun/CCL22 signal
Liang Ding et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2015)
Molecular Biology and Immunology of Head and Neck Cancer
Theresa Guo et al.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA (2015)
Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan
Nicolas van Baren et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors
Michael Platten et al.
FRONTIERS IN IMMUNOLOGY (2015)
Abstract 491: NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy.
Mario R. Mautino et al.
CANCER RESEARCH (2014)
Cutting Edge: DNA Sensing via the STING Adaptor in Myeloid Dendritic Cells Induces Potent Tolerogenic Responses
Lei Huang et al.
JOURNAL OF IMMUNOLOGY (2013)
Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma
Jin Ye et al.
VIRCHOWS ARCHIV (2013)
Tryptophan Catabolism in Cancer: Beyond IDO and Tryptophan Depletion
Michael Platten et al.
CANCER RESEARCH (2012)
Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer
Julie R. Brahmer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
Courtney Smith et al.
CANCER DISCOVERY (2012)
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
Douglas G. Altman et al.
PLOS MEDICINE (2012)
Upregulated Expression of Indoleamine 2, 3-Dioxygenase in Primary Breast Cancer Correlates with Increase of Infiltrated Regulatory T Cells In Situ and Lymph Node Metastasis
Jinpu Yu et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2011)
Expression and prognostic impact of indoleamine 2,3-dioxygenase in oral squamous cell carcinomas
Klaus Laimer et al.
ORAL ONCOLOGY (2011)
Increased tryptophan degradation in patients with bronchus carcinoma
A. B. Engin et al.
EUROPEAN JOURNAL OF CANCER CARE (2010)
Increased serum kynurenine/tryptophan ratio correlates with disease progression in lung cancer
Yuzo Suzuki et al.
LUNG CANCER (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
PD-1 and PD-1 ligands: from discovery to clinical application
Taku Okazaki et al.
INTERNATIONAL IMMUNOLOGY (2007)
Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer:: Effect on tumor-infiltrating T cells
G Brandacher et al.
CLINICAL CANCER RESEARCH (2006)
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells
A Okamoto et al.
CLINICAL CANCER RESEARCH (2005)
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
GQ Phan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
分享论文
